 |
|
|
| |
Incidence and Predictors of de Novo Hepatocellular Carcinoma Following Achievement of Sustained Virologic Response With Direct-Acting Antivirals: Results From the Gilead SVR and Cirrhosis Registries
|
| |
| |
Reported by Jules Levin
AASLD 2018 Nov 9-12 Boston
K. Rajender Reddy,1 Ira M. Jacobson,2 Armand Abergel,3 Barbara Leggett,4 Charles Landis,5 Robert H. Hyland,6 Frances Chen,6 Liyun Ni,6 Anu Osinusi,6 Diana M. Brainard,6 Jose Luis Calleja Panero,7 Eric Lawitz,8 Andrew Muir,9 Alessandra Mangia10
1University of Pennsylvania, Philadelphia; 2NYU School of Medicine, New York, NY; 3Centre Hospitalier Universitaire Estaing de Clermont-Ferrand, France; 4Faculty of Medicine, The University of Queensland, Brisbane, Australia; 5UW Medical Center, Seattle, WA; 6Gilead Sciences, Inc., Foster City, CA; 7Hospital Universitario Puerta de Hierro-Majadahonda, Spain; 8UT Health San Antonio, TX; 9Duke University School of Medicine, Durham, NC; 10Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy
References: 1. Ioannou GN, et al. J Hepatol 2018;68:25-32; 2. Nahon P, et al.
Gastroenterology 2018 Jul 19 [epub ahead of print]; 3. Kanwal F, et al. Gastroenterology. 2017;153:996-1005.e1; 4. Schwabe C, et al. AASLD 2018, poster 595. Acknowledgments: We extend our thanks to the registry participants. This study was funded by Gilead Sciences, Inc.
Disclosures: K.R. Reddy, B. Leggett, C. Landis, and J.L.C. Panero: nothing to disclose; I.M. Jacobson: Gilead, AbbVie, BMS, Janssen, MSD; A. Abergel: Gilead, AbbVie, MSD; R.H. Hyland, F. Chen, L. Ni, A. Osinusi, and D.M. Brainard: Gilead; E. Lawitz: Gilead, AbbVie; A. Muir: Gilead, AbbVie, Dova, NGM, Oncimmune, Proteus, TaiwanJ; A. Mangia: Gilead, BMS, Janssen, MSD, Roche.
|
| |
|
|
|
|
|
